Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Immedica: exclusive EUMENA commercialization rights, $35M upfront; Immedica will not pursue regulatory approval in licensed territories (upfront recognized as revenue Jun 2026). Fred Hutchinson Cancer Research Center: exclusive apamistamab antibody license; $1M FDA-approval milestone; 2% royalties
Indications
Bone marrow transplant conditioning (R/R AML)(Phase 3)
Status note SIERRA Phase 3 trial completed. Company actively seeking strategic partner for pivotal development and commercialization. Securities litigation re SIERRA disclosures pending (motion to dismiss, as of filing).
Iomab-ACT
Stage not disclosed · ActiveModality: radiopharmaceutical
Target CD45
Indications
Conditioning for cell & gene therapies (NHL)(Stage not disclosed)
Status note Targeted conditioning agent for cell & gene therapies; clinical trials executed across Actimab-A/Iomab-ACT programs per filing, but stage for Iomab-ACT not specified.
Partnerships Undisclosed third party: exclusive worldwide license (Jun 25, 2024) for radiopharmaceutical products incorporating a licensed monoclonal antibody; upfront + development/regulatory/commercial milestones and royalties (amounts not disclosed)
Indications
mCRPC(Preclinical)
NSCLC(Preclinical)
Breast cancer (HR+/HER2-, HER2+, TNBC)(Preclinical)
Status note Targets a novel non-PSMA antigen (name not disclosed). Preclinical translational data presented at AACR Apr 21, 2026.
Per-asset detail extracted from the 10-Q filed 2026-08-07. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 2 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.